Litcius/Paper detail

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Lauren C. Tindale, Jason S. Richardson, Deborah M. Anderson, Jason Mendy, Sufia Muhammad, Tobi Loreth, Sarah Royalty Tredo, Roshan Ramanathan, Victoria A. Jenkins, Lisa Bedell, Patrick Ajiboye

2025The Lancet42 citationsDOI

Topics & Concepts

ImmunogenicityMedicinePlaceboVirusChikungunyaVirologyDouble blindRandomized controlled trialVirus-like particleChikungunya feverImmunologyInternal medicineAlternative medicineAntibodyBiologyRecombinant DNAPathologyBiochemistryGeneMosquito-borne diseases and controlBiological Research and Disease StudiesViral Infections and Outbreaks Research
Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial | Litcius